Pacific Bio (PACB) Reports In-Line Q4 EPS, Reports $30M Stock Offering

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $16.9 million versus the consensus estimate of $14.9 million.

On February 3, 2015, the Company announced its intention to issue and sell up to $30,000,000 of shares of its common stock, par value $0.001 per share, from time to time, through an “at-the-market” equity offering under which Cantor will act as sales agent.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs